Incyte (INCY) is a publicly traded Healthcare sector company. As of May 20, 2026, INCY trades at $97.40 with a market cap of $19.02B and a P/E ratio of 36.15. INCY moved +1.56% today. Year to date, INCY is -4.63%; over the trailing twelve months it is +48.67%. Its 52-week range spans $53.56 to $112.29. Analyst consensus is buy with an average price target of $109.13. Rallies surfaces INCY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded INCY stock?
Recent politician trading activity in INCY includes disclosures from Rob Bresnahan and Ro Khanna. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
INCY Key Metrics
Key financial metrics for INCY
Metric
Value
Price
$97.40
Market Cap
$19.02B
P/E Ratio
36.15
EPS
$2.67
Dividend Yield
0.00%
52-Week High
$112.29
52-Week Low
$53.56
Volume
704.20K
Avg Volume
0
Revenue (TTM)
$3.70B
Net Income
$597.60M
Gross Margin
93.10%
Congressional Trades in INCY
Rob Bresnahan sale INCY on May 15, 2025 (amount: $15.00K).
Ro Khanna sale INCY on Sep 9, 2024 (amount: $15.00K) for Spouse.
Recent politician trading activity in INCY includes disclosures from Rob Bresnahan and Ro Khanna. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in INCY?
Yes. Rallies tracks politician and congressional stock disclosures for INCY, including reported purchases, sales, dates, owners, and trade amounts when available.
Is INCY research on Rallies investment advice?
No. Rallies provides research, data, and educational context for INCY. It does not provide personalized investment advice.
